AlphAIAlphAI — Financial news for AI agents
investing.com$HIMS

Hims & Hers earnings analysis: questions answered and next catalysts

Hims & Hers Health (HIMS) reported Q3 FY2026 revenue of $890.4M, up 49% YoY but slightly below estimates. Adjusted EPS was -$0.14, missing expectations. Management raised international revenue outlook and expects positive free cash flow for 2026-2027. The stock is down 19.53% as of Nov 10, 2026, following a 40% drop in the prior month. Key catalysts include the Peptides+ launch and Q4 earnings.

Original reporting
investing.com
Published Nov 10, 2026, 5:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 6:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HIMS
Bearish
high confidence
Mentioned
$HIMS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

The earnings miss and guidance reduction are likely to drive the stock lower in the short term.

02

Market read

Earnings release provides fresh data that can affect trading decisions on HIMS today.

03

What to watch

Positive free‑cash‑flow outlook and upcoming peptide launch may support longer‑term upside.

Relevance 8/10Novelty 8/10Timing: post‑earnings reaction today

Background

Hims & Hers Health reported Q3 FY2026 results with revenue up 49% YoY but missed EPS expectations and cut FY EBITDA guidance.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Q3 FY2026 earnings miss with adjusted EPS of -$0.14 vs +$0.06 est and lowered FY2026 EBITDA guidance.

Expected impact

likely pressure as the market prices in the EPS miss and EBITDA guide reduction

Evidence & confidence

The company posted a sizable revenue beat but a sharp EPS miss and lowered EBITDA outlook, which typically triggers sell‑offs.

Market effects

Sector

Telehealth and digital health peers may see spill‑over pressure from HIMS miss.

Regional

U.S. small‑cap health tech segment could face slight pullback.

Global

Limited; impact confined to U.S. listed health‑tech stocks.

Counterpoint

What could challenge this read

Weight‑loss and international growth could offset short‑term earnings weakness.

Key entities

  • company
    Hims & Hers Health

    U.S. telehealth company (ticker HIMS) reporting Q3 FY2026 earnings.

Read at source← All news

StoryHims & Hers Reports Strong Q3 Revenue Growth but Cuts 2026 Profit Outlook

Also covered by

5 outlets

Related articles

$HIMSMedAI 8/10

Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week

Hims & Hers (HIMS) shares fell 25.67% last week, despite a deal with Eli Lilly (LLY) announced on November 6. HIMS reported Q3 revenue of $890.37M, up 48.65%, but margins dropped to 57% from 74%. Lilly's Q3 revenue rose 38.61% to $24.397B, and it raised its full-year outlook to $91B-$92B. HIMS's subscriber base shrank by 100,000 to 2.8M, and it cut full-year Adjusted EBITDA guidance to $257M-$277M.

247wallst.com
$HIMSHighAI 8/10

Hims & Hers Health Inc (HIMS) (Q3 2026) Earnings Call Highlights: Revenue Surges 49%

Hims & Hers Health Inc. (HIMS) reported Q3 2026 revenue growth of 49%, but subscribers declined by 100,000 to 2.8 million due to reduced marketing. Gross margins fell to 57%, and GAAP net loss was $33 million. Full-year adjusted EBITDA guidance was lowered to $257-$277 million. The company plans to increase marketing and expects subscriber growth to recover in Q1 2027. Management discussed strategic shifts, including peptide launches and international expansion.

finance.yahoo.com
$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.

finance.yahoo.com
$HIMSHighAI 8/10

Hims & Hers Stock Falls 15% on Weak Q4 Revenue Outlook

Hims & Hers Health (HIMS) shares dropped 15% after the company issued Q4 revenue guidance below expectations, forecasting $875M–$895M vs. analysts' $955.1M estimate. Q3 revenue grew 49% to $890.4M but gross margin declined to 57% from 74%. The company also faces regulatory challenges over weight-loss medications and data privacy.

grafa.com